북미의 외용제 CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 서비스 유형별, 스폰서별, 국가별, 부문별 예측(2024-2030년)

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 26.45 billion by 2030, registering a CAGR of 10.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

• Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 65.0% share in 2023, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
• Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
• Based on sponsors, the pharmaceutical companies segment held the largest market share in 2023. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
• The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in the U.S.
  • 1.5.2. Data for primary interviews in Canada
• 1.6. Information or Data Analysis
  • 1.6.1. Data analysis models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity flow analysis (Model 1)
  • 1.8.2. Approach 1: Commodity flow approach
  • 1.8.3. Parent Market Analysis (Model 2)
  • 1.8.4. Approach 2: Parent Market Analysis
• 1.9. List of Secondary Sources
• 1.10. List of Primary Sources
• 1.11. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Technological advancements & growing R&D investments
    • 3.2.1.2. Rising demand for topical medications
    • 3.2.1.3. Expansion of manufacturing capacities and partnerships
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance with strict regulatory requirements
    • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
• 3.3. North America Topical Drugs CDMO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
• 3.4. Pricing Analysis
• 3.5. Topical Drugs CDMO Capacity Outlook
  • 3.5.1. CDMO Manufacturing Container Capacity
  • 3.5.2. Topical Drugs Container Capacity By Product Type
• 3.6. North America Topical Drugs CDMO Market Outlook By Product Category
  • 3.6.1. North America Topical Drugs CDMO Market Share, By Product Category, 2023 (%)
  • 3.6.2. Prescription Drugs
    • 3.6.2.1. Segment Overview
    • 3.6.2.2. Major Prescription Drugs, By Product Type
  • 3.6.3. Generic Drugs
    • 3.6.3.1. Segment Overview
    • 3.6.3.2. Major Generic Drugs, By Product Type
  • 3.6.4. Over-the-counter (OTC) Drugs
    • 3.6.4.1. Segment Overview
    • 3.6.4.2. Major OTC Drugs, By Product Type
• 3.7. Impact of COVID-19 Pandemic

Chapter 4. North America Topical Drugs CDMO Market: Product Type Estimates & Trend Analysis

• 4.1. Product Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. North America Topical Drugs CDMO Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Semi-solid Formulations
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Creams
    • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Ointments
    • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Lotions
    • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Others
    • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Liquid Formulations
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Suspensions
    • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Solutions
    • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Solid Formulations
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Transdermal Products
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Type Estimates & Trend Analysis

• 5.1. Service Type Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. North America Topical Drugs CDMO Market by Service Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Contract Development
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.2. Formulation Development
    • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Analytical Testing
    • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.4. Stability Testing
    • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.5. Others
    • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Contract Manufacturing
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Clinical
    • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Commercial
    • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: Sponsors Estimates & Trend Analysis

• 6.1. Sponsors Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. North America Topical Drugs CDMO Market by Sponsors Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Pharmaceutical Companies
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Biopharmaceutical Companies
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Others
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

• 7.1. Country Market Share Analysis, 2023 & 2030
• 7.2. Country Market Dashboard
• 7.3. Country Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. U.S.
  • 7.5.1. Key country dynamics
  • 7.5.2. Regulatory framework
  • 7.5.3. Competitive scenario
  • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Canada
  • 7.6.1. Key country dynamics
  • 7.6.2. Regulatory framework
  • 7.6.3. Competitive scenario
  • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
  • 8.1.1. Innovators
  • 8.1.2. Market Leaders
  • 8.1.3. Emerging Players
  • 8.1.4. Company Market Share Analysis, 2023
• 8.2. Company Profiles
  • 8.2.1. The Lubrizol Corporation
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product/service benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Cambrex Corporation
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product/service benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Contract Pharmaceuticals Limited
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product/service benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Bora Pharmaceutical CDMO
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product/service benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Ascendia Pharmaceuticals
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product/service benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. Pierre Fabre S.A.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product/service benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. Piramal Pharma Solutions
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product/service benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. DPT Laboratories, LTD.
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product/service benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. MedPharm Ltd.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product/service benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. Zenvisionpharma
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product/service benchmarking
    • 8.2.10.4. Strategic initiatives